These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293 [TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536 [TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206 [TBL] [Abstract][Full Text] [Related]
6. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744 [TBL] [Abstract][Full Text] [Related]
7. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. Prasithsirikul W; Bunnag P J Med Assoc Thai; 2004 Feb; 87(2):166-72. PubMed ID: 15061300 [TBL] [Abstract][Full Text] [Related]
8. Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism. Samaras K; Wand H; Law M; Emery S; Cooper DA; Carr A Curr HIV Res; 2009 Jul; 7(4):454-61. PubMed ID: 19601783 [TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065 [TBL] [Abstract][Full Text] [Related]
13. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. Blümer RM; van der Valk M; Ackermans M; Endert E; Serlie MJ; Reiss P; Sauerwein HP Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1097-104. PubMed ID: 19690066 [TBL] [Abstract][Full Text] [Related]
14. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Barbaro G Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554 [TBL] [Abstract][Full Text] [Related]
15. Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions. Okada S; Konishi M; Ishii H BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26917795 [TBL] [Abstract][Full Text] [Related]
16. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Magkos F; Brennan A; Sweeney L; Kang ES; Doweiko J; Karchmer AW; Mantzoros CS Metabolism; 2011 Jul; 60(7):1045-9. PubMed ID: 21081243 [TBL] [Abstract][Full Text] [Related]
17. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817 [TBL] [Abstract][Full Text] [Related]
19. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. Calmy A; Hirschel B; Hans D; Karsegard VL; Meier CA AIDS; 2003 Mar; 17(5):770-2. PubMed ID: 12646807 [No Abstract] [Full Text] [Related]
20. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]